Status:

WITHDRAWN

Curcumin in Pediatric Ulcerative Colitis

Lead Sponsor:

Schneider Children's Medical Center, Israel

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

6-18 years

Phase:

PHASE3

Brief Summary

Background: Curcumin in an active phytochemical substance, used as part of the human diet, that has anti-inflammatory and anti-oxidative properties which were demonstrated in multiple experimental mod...

Detailed Description

Clinical efficacy of induction and maintenance medications in pediatric UC is limited with a cumulative long-term risk of 20%-30% for colectomy. Remission rates following induction with corticosteroid...

Eligibility Criteria

Inclusion

  • Diagnosis of UC, established by the presence of accepted clinical, radiologic, endoscopic and histologic criteria.
  • Age: 6 - 18 years (inclusive).
  • PUCAI 10-65 at enrollment
  • Negative stool culture, parasites and clostridium toxin
  • Ability and acceptance to participate in the study and follow study procedures, as evidenced by a parent/legal guardian signing a written informed consent and the child providing assent.

Exclusion

  • Acute severe UC (PUCAI\>65 points) requiring IV corticosteroids.
  • History of two relapses or more on 5-ASA treatment.
  • Pregnancy
  • Sepsis or active bacterial infection
  • Fever \>38.5 degrees.
  • Patients whose disease is confined to the rectum (i.e. proctitis).
  • Patients with crohn's colitis or with IBD type unclassified (IBD-U) according to Montreal classification.
  • Rectal therapies (suppositories, foams, enemas etc) of all kind are allowed if the dose and frequency has remained stable during the previous 14 days prior to the screening visit.
  • Known allergy to 5ASA, salicylates, or aminosalicylates.
  • History of recurrent pancreatitis.
  • Existence of current renal disease, or a screening blood urea nitrogen (BUN) or creatinine value that is \> 1.5 times the upper limit of the age appropriate normal.
  • \-

Key Trial Info

Start Date :

March 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT02277223

Start Date

March 1 2020

End Date

December 31 2022

Last Update

October 1 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Schneider Medical Center

Petah Tikva, Israel, 4259000